GleamWall
中文EN

ENVB Enveric Biosciences, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 890821 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY3.4%
TTM EPS YoY97.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-204.8%
ROA-175.2%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets10.1%
Debt / equity0.00x
Current ratio9.70x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.97x
Accruals ratio-5.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$1.35M$1.36M$345,969$372,178$402,417$1.26M$746,371$1.10M
SG&A expense$1.17M$1.64M$1.25M$1.78M$1.43M$1.22M$1.36M$1.99M
Operating income-$2.56M-$3.03M-$1.63M-$2.19M-$1.87M-$2.52M-$2.19M-$3.17M
Pretax income-$2.55M-$3.03M-$1.63M-$2.19M-$1.87M-$2.52M-$2.18M-$3.15M
Income tax———————$7,199
Net income-$2.55M-$3.03M-$1.63M-$2.19M-$1.87M-$2.52M-$2.18M-$3.15M
EBITDA-$2.53M-$2.99M-$1.60M-$2.15M-$1.83M-$2.48M-$2.11M-$3.09M
EPS (basic)-0.57-0.76-1.08—-10.81-11.65-14.58—
EPS (diluted)-0.57-0.76-1.08—-10.81-11.65-14.58—
Weighted avg. shares (diluted)4.48M3.99M1.51M—313,242216,311149,815—
Banking
Net interest income-$266-$292-$303-$250$274-$132$2-$225
Balance sheet
Cash & equivalents$5.61M$8.30M$4.91M$4.68M$3.76M$2.85M$4.29M$2.24M
Current assets$6.25M$8.79M$5.38M$4.94M$4.17M$3.31M$4.83M$2.73M
PP&E, net$47,622$81,929$119,927$159,234$196,521$241,082$267,279$305,777
Intangibles———————$42,182
Total assets$6.37M$8.94M$5.52M$5.10M$4.36M$3.55M$5.10M$3.08M
Current liabilities$644,202$861,475$460,676$918,400$905,885$1.36M$1.18M$1.49M
Total liabilities$644,202$861,475$460,676$918,400$905,885$1.36M$1.18M$1.49M
Shareholders' equity$5.73M$8.08M$5.06M$4.18M$3.46M$2.18M$3.92M$1.59M
Shares outstanding4.48M3.94M1.89M1.06M518,2963.03M2.47M56,501
Cash flow statement
Operating cash flow-$2.65M-$2.44M-$2.26M-$1.78M-$2.07M-$1.89M-$2.39M-$1.31M
Financing cash flow-$29,055$5.84M$2.50M$2.69M$2.99M$449,096$4.45M$463,448
Depreciation & amortization$34,919$36,826$37,240$39,485$40,369$39,980$81,024$82,487
Stock-based compensation$198,546$125,114$88,673$240,234$186,567$205,846$193,848$471,676

Free plan shows the latest 8 periods; Pro shows all 66 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.